Company news
Paradigm Biopharmaceuticals Ltd. news in 2020
Paradigm Biopharmaceuticals Ltd.'s news releases, calls and decks from 2020, newest first.
R&D Investor Presentation
December 20, 2020
Paradigm receives postive feedback from FDA type c meeting
December 17, 2020
Paradigm Provides Phase 3 Clinical Trial Update
December 13, 2020
First patient dosed in MPS-I Phase 2 clinical trial
November 11, 2020
Zilosul reduces pain in patients with knee OA
September 30, 2020
Extension of exclusive agreement with bene pharmaChem
September 28, 2020
EMA provides key path toward phase 3 trials and registration
September 27, 2020
Paradigm Presentation to Emerging Leaders Conference
September 16, 2020
Appendix 4E and 2020 Annual Report
August 27, 2020
MPS receives critical approvals and feedback from agencies
August 10, 2020
Quarterly Activities Report
July 31, 2020
EAP - 65% pain reduction in 10 OA patients in usa
July 29, 2020
New financial year update
July 15, 2020
S&P DJI Announces June 2020 Quarterly Rebalance
June 11, 2020
Block trade to institutional investors
May 12, 2020
EAP treatment completed and Orphan Status achieved for MPS-I
April 30, 2020
Reinstatement to Official Quotation
April 8, 2020
Paradigm completes $35m raising
April 7, 2020
Paradigm Reports Very Encouraging Real World Data
April 6, 2020
Paradigm receives clarity on US regulatory pathway
April 5, 2020
Paradigm Latest Corporate Presentation
April 5, 2020
Voluntary Suspension
April 5, 2020
All 10 participants in US FDA EAP have commenced treatment
March 23, 2020
Paradigm reports Positive Pre-IND meeting with US FDA
February 20, 2020
Paradigm - first patient dosed in USA under FDA approved EAP
February 17, 2020
Paradigm presents MPS VI poster at WORLD Symposium
February 12, 2020
Decks in 2020
- Investor Presentation (December 2020)
Investor deck · 23 slides · Dec 21, 2020
- Shareholder Meeting (November 2020)
Shareholder meeting · 17 slides · Nov 19, 2020
- Investor Presentation (April 2020)
Investor deck · 32 slides · Apr 6, 2020